Key facts
- Notable investors include Fortune Capital, Capitallink, China-Singapore Suzhou Industrial Park Development Investment, Fortune Haven Capital, Gansu State Investment Fund — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for IxCell Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for IxCell Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About IxCell Biotechnology
Manufacturer of advanced bioseparation media and chromatography products aims to support high-purity biopharmaceutical production and diagnostic applications. The company's offerings feature protein A resins, ion-exchange and size-exclusion chromatography materials, and customizable purification systems for bioprocess workflows, helping biotech firms, pharmaceutical manufacturers, and diagnostic labs achieve consistent purity, yield, and scalability, enabling efficient and reliable separation infrastructure across life-science industries.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2013
- Employees
- 78
- Website
- ixcellbio.com/
- Ownership
- Privately Held (backing)
IxCell Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in IxCell Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on IxCell Biotechnology in its N-PORT filings yet. We sweep new filings monthly.